Clinical Trials Browser

Phase 2 × eprenetapopt × Gynecologic × Clear all

NCT03268382 2025-03-17

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Phase 2 Completed

36 enrolled 13 charts

Ovarian Neoplasms, Recurrence